BioXcel Therapeutics Inc. announced the completion of an updated market opportunity assessment for Igalmi (dexmedetomidine) for acute agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient)… read more.
Vir Biotechnology announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, Pro -xten dual-masked T-cell engager (TCE) being evaluated in… read more.
Iovance Biotherapeutics Inc. announced data demonstrating a best-in-class profile for commercial Amtagvi (lifileucel) with unprecedented response rates in a real-world clinical, retrospective study in patients with advanced (unresectable… read more.
Moderna Inc. announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorised its updated COVID-19 mRNA vaccine, Spikevax targeting the SARS-CoV-2 LP.8.1 variant, for adults… read more.
Novocure announced that the FDA approved Optune Pax, Tumor Treating Fields (TTFields) device for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and… read more.
Citius Oncology Inc., the oncology-focused subsidiary of Citius Pharmaceuticals Inc. announced that it has entered into an exclusive distribution agreement with Uniphar , a leading international healthcare services… read more.
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE)–Feb. 12, 2026– KalVista Pharmaceuticals, Inc…. read more.
PTC Therapeutics Inc. announced that it has withdrawn the New Drug Application (NDA) resubmission for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) following… read more.
Key data from Merck’s portfolio and pipeline to be presented at the 2026 ASCO GU Cancers Symposium: First-time data from the Phase 3 KEYNOTE-B15/EV-304 trial evaluating KEYTRUDA, Merck’s… read more.
Biofrontera Inc. announced that the FDA has completed its filing review and accepted filing of the Company’s supplemental New Drug Application (sNDA) for Ameluz (aminolevulinic acid hydrochloride) topical… read more.
Ono Pharmaceutical Co., Ltd. announced that the FDA has accepted for filing the New Drug Application (NDA) under the accelerated approval pathway for tirabrutinib, a highly selective irreversible,… read more.
Pfizer Inc. announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating Braftovi (encorafenib) in combination with cetuximab (Erbitux) and FOLFIRI (fluorouracil,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
